Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States. The collaboration combines Guardant Health's suite of cutting-edge precision oncology diagnostics with Trial Library's AI-powered matching and patient navigation platform. Together, the comp.

Business Wire • Dec 11, 2025

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

PALO ALTO, Calif. & ROME--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking.

Business Wire • Dec 9, 2025

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD.

Business Wire • Dec 5, 2025

Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?

Here is how Guardant Health (GH) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 4, 2025

Senator Buys Coca-Cola, Hershey's Stock After Selling Magnificent Seven Stocks In 2025

A member of Congress who has actively been trading Magnificent Seven stocks in 2025 announced three recent stock purchases, including two food and beverage stocks ahead of the 2025 holidays.

Benzinga • Dec 3, 2025

5 Top Stocks For AI Fatigue

Turkey isn't the only thing making investors tired this Thanksgiving: AI fatigue is setting in as bubble fears rise and tech trades at dot-com era multiples. Record AI spending continues despite skepticism over near-term payoffs and many firms reporting zero measurable returns. AI investment could reach $4 trillion by 2030, while tech leaders acknowledge the risk of irrational spending and the potential for a bubble to burst.

Seeking Alpha • Nov 28, 2025

These 15 stocks are still showing momentum — and a market-beating edge

“Big mo” stock strategies have lost their advantage, but these companies display relative strength.

Market Watch • Nov 20, 2025

6 Healthcare Stocks With Strong Upward Momentum

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.

Benzinga • Nov 18, 2025

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often disruptive, time-consuming, and ultimately costly due to progressively larger data sets needing faster solutions. SN.

Business Wire • Nov 12, 2025

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels in a patient's blood to predict outcomes sooner than imaging without the need for a tissue sample. Building on.

Business Wire • Nov 10, 2025